Provectus Biopharmaceuticals (OTC: PVCT) specializes in developing oncology and dermatology therapies. Its novel investigational drug for cancer, PV-10, is designed for injection into solid tumors, thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and liver cancers. The company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase II trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company’s website at www.pvct.com